Jan‐Michel Heger

548 total citations
23 papers, 82 citations indexed

About

Jan‐Michel Heger is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Jan‐Michel Heger has authored 23 papers receiving a total of 82 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 10 papers in Oncology and 5 papers in Neurology. Recurrent topics in Jan‐Michel Heger's work include Lymphoma Diagnosis and Treatment (14 papers), CAR-T cell therapy research (6 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Jan‐Michel Heger is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), CAR-T cell therapy research (6 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Jan‐Michel Heger collaborates with scholars based in Germany, United States and Australia. Jan‐Michel Heger's co-authors include Peter Borchmann, Dennis A. Eichenauer, Boris Böll, Alexander Shimabukuro‐Vornhagen, Christof Scheid, Udo Holtick, Matthias Kochanek, Philipp Gödel, Jörg Mahlich and Michael Hallek and has published in prestigious journals such as Blood, British Journal of Haematology and Frontiers in Oncology.

In The Last Decade

Jan‐Michel Heger

18 papers receiving 80 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan‐Michel Heger Germany	6	56	31	15	13	13	23	82
Moraima Jiménez Spain	4	41 0.7×	25 0.8×	28 1.9×	10 0.8×	12 0.9×	10	93
Betsy Valles United States	5	23 0.4×	14 0.5×	19 1.3×	15 1.2×	16 1.2×	5	79
Grażyna Karolczyk Poland	6	26 0.5×	13 0.4×	25 1.7×	8 0.6×	14 1.1×	13	76
H Schouten Netherlands	5	53 0.9×	38 1.2×	22 1.5×	5 0.4×	11 0.8×	6	81
Kannadit Prayongratana Thailand	5	32 0.6×	11 0.4×	42 2.8×	7 0.5×	8 0.6×	20	75
Mika Kohri Japan	7	58 1.0×	62 2.0×	25 1.7×	2 0.2×	34 2.6×	19	106
Asif Alavi United States	6	17 0.3×	13 0.4×	41 2.7×	12 0.9×	12 0.9×	14	74
Audrey M. Sigmund United States	6	45 0.8×	32 1.0×	46 3.1×	5 0.4×	21 1.6×	22	116
Alyssa DiGilio United States	4	44 0.8×	33 1.1×	84 5.6×	7 0.5×	45 3.5×	11	123
Anne Banet France	5	25 0.4×	8 0.3×	41 2.7×	3 0.2×	21 1.6×	12	62

Countries citing papers authored by Jan‐Michel Heger

Since Specialization

Citations

This map shows the geographic impact of Jan‐Michel Heger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan‐Michel Heger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan‐Michel Heger more than expected).

Fields of papers citing papers by Jan‐Michel Heger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan‐Michel Heger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan‐Michel Heger. The network helps show where Jan‐Michel Heger may publish in the future.

Co-authorship network of co-authors of Jan‐Michel Heger

This figure shows the co-authorship network connecting the top 25 collaborators of Jan‐Michel Heger. A scholar is included among the top collaborators of Jan‐Michel Heger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan‐Michel Heger. Jan‐Michel Heger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wendler, Julia, Richard Lewis, Elke Valk, et al.. (2025). Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma. Haematologica. 110(6). 1384–1388.

Heger, Jan‐Michel, Jonathan M. Weiss, Christian Becker, et al.. (2024). Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR. European Journal Of Haematology. 112(6). 957–963. 5 indexed citations

Heger, Jan‐Michel, et al.. (2024). Survival outcomes of patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation in Germany: real-world evidence from an administrative database between 2010 and 2019. Frontiers in Oncology. 14. 1432310–1432310.

Heger, Jan‐Michel, Jan‐Hendrik Naendrup, Florian Simon, et al.. (2024). Marked hyperferritinemia in critically ill cancer patients. European Journal Of Haematology. 113(4). 493–500.

Naendrup, Jan‐Hendrik, et al.. (2024). Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single‐center retrospective analysis. Hematological Oncology. 42(5). e3300–e3300. 1 indexed citations

Borchmann, Peter, et al.. (2023). Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database. Journal of Cancer Research and Clinical Oncology. 149(10). 7091–7101. 7 indexed citations

Heger, Jan‐Michel, Boris Böll, Jan‐Hendrik Naendrup, et al.. (2023). Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis. Leukemia Research. 132. 107352–107352. 4 indexed citations

Heger, Jan‐Michel, et al.. (2023). Clinical applications of circulating tumor DNA in Hodgkin lymphoma. Seminars in Hematology. 60(3). 157–163. 1 indexed citations

Shi, Zhiyuan, et al.. (2023). P1384: MULTI-EFFECTOR IMMUNE CELL RETARGETING USING A BISPECIFIC SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY IN AGGRESSIVE B CELL LYMPHOMAS. HemaSphere. 7(S3). e49676c6–e49676c6.

10.

Kaddu‐Mulindwa, Dominic, Philipp Gödel, Nadine Kutsch, et al.. (2022). Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(7). e498–e506. 1 indexed citations

11.

Borrega, Jorge Garcia, Boris Böll, Matthias Kochanek, et al.. (2022). Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis. Annals of Hematology. 102(1). 191–197. 2 indexed citations

12.

Borchmann, Peter, et al.. (2022). Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Health Claims Data Analysis. Oncology and Therapy. 11(1). 65–81. 7 indexed citations

13.

Pluetschow, Annette, Vladan Vučinić, Helmut Ostermann, et al.. (2022). JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO). European Journal Of Haematology. 109(6). 728–735. 7 indexed citations

14.

Becker, Jürgen C., Jan‐Hendrik Naendrup, Jorge Garcia Borrega, et al.. (2022). Teamspezifische Auswirkungen der Corona-Pandemie auf Mitarbeiter:innen der Internistischen Intensivmedizin eines Krankenhauses der Maximalversorgung. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 118(7). 556–563. 2 indexed citations

15.

Heger, Jan‐Michel, Philipp Gödel, Hyatt Balke‐Want, et al.. (2022). Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing. Blood. 140(Supplement 1). 3537–3538. 1 indexed citations

16.

Borrega, Jorge Garcia, Jan‐Michel Heger, Philipp Koehler, et al.. (2021). Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes—results of a retrospective analysis from a German university hospital. Annals of Hematology. 101(2). 389–395. 9 indexed citations

17.

Naendrup, Jan‐Hendrik, Philipp Gödel, Hyatt Balke‐Want, et al.. (2021). Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine. European Journal Of Haematology. 107(2). 202–210. 2 indexed citations

18.

Gödel, Philipp, Jan‐Michel Heger, Nadine Kutsch, et al.. (2021). Hematologic Rescue of CAR T-cell–mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient. HemaSphere. 5(3). e545–e545. 15 indexed citations

19.

Hüttmann, Andreas, Vladan Vučinić, Horst Müller, et al.. (2021). Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i). British Journal of Haematology. 196(3). 606–616. 4 indexed citations

20.

Heger, Jan‐Michel, Dennis A. Eichenauer, Philipp Kasper, et al.. (2019). Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy. European Journal Of Haematology. 103(3). 268–271. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact